top of page
Connecting Dots

ALS | Parkinson's Disease | Cancer
Stroke | Alzheimer's Disease

Asha Therapeutics logo-01-2 copy_edited.

A Robust Pipeline

of Disease Modifying
Medicines

image.png

PIPELINE

Pipeline.tif

Target Overview - Lead Development Candidate Programs

ASHA-624
SARM1 in Axonal Degeneration
and Neuronal Cell Death

ASHA-624 is a novel molecular glue that inhibits SARM1-mediated axonal degeneration, restoring normal homeostasis.

DISEASE INDICATIONS

- Amyotrophic Lateral Sclerosis (ALS)

- Glaucoma

- Spinal Cord Injury

- Peripheral Neuropathies

7NAL_edited.png

ASHA-091
DRP-1 Mediated Mitochondrial
Hyper-Fragmentation

ASHA-091 is a first-in-class highly specific inhibitor of pathological DRP1 activation and restores normal mitochondrial homeostasis and function

DISEASE INDICATIONS

- Parkinson's Disease

- Amyotrophic Lateral Sclerosis (ALS)

- Infectious Diseases & ME/CFS, Long COVID

- Ischemia/Reperfusion Injuries

4H1U_edited.png

ASHA-044
β-Catenin in Oncology 

ASHA-044 is a breakthrough first-in-class UbiPRISM™ degrader targeting β-Catenin by establishing a synthetic destruction complex to restore normal β-Catenin signaling

DISEASE INDICATIONS

- Colorectal Cancer

- Heptaocellular Carcinoma

- Melonoma

1JPW_edited.png
Connecting Dots
asha color.png
  • LinkedIn
  • Twitter

© Copyright 2023 Asha Therapeutics, all rights reserved 

Privacy Policy | Terms of Use

Website designed & maintained by A-Cubed Media Group

bottom of page